PT Kalbe Farma Tbk
PTKFF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.95B
Close$
$0.17
295.3% upside
Current Fair Value
295.3% upsideUndervalued by 295.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.95 Billion |
|---|---|
| Enterprise Value | $-4,094,522,934,651.00 |
| Dividend Yield | $0.00 (2.70%) |
| Earnings per Share | $80.51 |
| Beta | -0.04 |
| Outstanding Shares | 45,252,046,000 |
Return
| Return on Equity | 12.17% |
|---|---|
| Return on Assets | 9.24% |
| Return on Invested Capital | 14.41% |
Valuation & Multiples
| P/E Ratio | 9.26 |
|---|---|
| PEG | -219.15 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.15 |
| Enterprise Value to EBIT | -1.07 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 4, 2026
EPS Estimate
$0.00
Average shareholder expectationRevenue Estimate
$559.05 M
Average shareholder expectationNext Earnings Call
Expected Date
July 24, 2026
EPS Estimate
$0.00
Average shareholder expectationRevenue Estimate
$580.86 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PT Kalbe Farma Tbk
CEO: Vidjongtius PT Kalbe Farma Tbk engages in the development, distribution, and trading of pharmaceutical products. It operates through the following segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. T...